This is a routine insider transaction by a non-executive affiliate; traders should monitor for actual execution but no immediate price impact is expected. The sale represents a small fraction of the company's $1.5B market cap and does not signal material concern.
IMCR drugs
IMCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $31.85entry
- T+1 · 7mo ago −0.13%α −0.70% · $31.81
- T+5 · 7mo ago −0.66%α −4.18% · $31.64
- T+20 · 7mo ago −9.45%α −18.00% · $28.84
- T+60 · 4mo ago +2.04%α −8.42% · $32.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
David Berman, an affiliate of Immunocore Holdings plc, filed a Form 144 to notify intent to sell 25,000 ADRs, representing approximately $796,250 based on current market value. The sale is planned for April 9, 2026, via a cashless exercise and sale through J.P. Morgan Securities LLC.
Key Facts
- Reporting person: David Berman, identified as an affiliate of the company
- Number of securities intended for sale: 25,000 ADRs
- Estimated value of the proposed sale: $796,250 (based on $31.85 per ADR)
- Planned sale date: April 9, 2026
- Method of sale: Same-day cashless exercise and sale
- Broker: J.P. Morgan Securities LLC acting as agent and attorney in fact
Financial Impact
Approximately $796,250 in ADRs to be sold
Risk Factors
- Potential short-term negative sentiment if market interprets sale as lack of confidence
- Execution risk that sale may occur at a different volume or price than disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974494-26-000149 |
| Document: 0001974494-26-000149-index.html | 0001974494-26-000149 |
| Document: 0001974494-26-000149.txt | 0001974494-26-000149 |
Track record
14 reports on IMCR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers